Investigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma

Basit Öğe Kaydı
dc.authoridÇELIKKOL, ALIYE/0000-0002-3799-4470
dc.authorwosidÇELIKKOL, ALIYE/ABE-2695-2020
dc.contributor.authorTunçkale, Tamer
dc.contributor.authorÇalışkan, Tezcan
dc.contributor.authorPotoğlu, Bilgehan
dc.contributor.authorEngin, Taner
dc.contributor.authorGüzel, Savaş
dc.contributor.authorÇelikkol, Aliye
dc.contributor.authorYılmaz, Ahsen
dc.date.accessioned2023-05-06T17:22:11Z
dc.date.available2023-05-06T17:22:11Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractOBJECTIVE: The aim of this study is to determine biomarkers, which may be used in order to understand the pathophysiology, the diagnosis, progression surveillance/monitoring, and treatment efficacy of high graded glial tumors.BACKGROUND: Radiological imaging in the diagnosis and relapse surveillance of glial tumors is sometimes insufficient. There is need for additional methods of diagnosis and surveillance in order to rule out contradictory circumstances.METHOD: Using enzyme like immune sorbent assay method, E-Cadherin, Tenascin C, Tetraspanin 8, Survivin and VEGF121 levels were investigated in serum and tumor tissues of 28 patients diagnosed with pathological glioblastoma, and in the serum of 26 healthy individuals. Correlation between tumor tissue values and Ki67 percentage, and P53 mutation, and difference between unhealthy and healthy serum levels were sought.RESULTS: It was found out that E-Cadherin and VEGF 121 levels in the unhealthy serum were high in comparison to the control group (p < 0.05). In the patient group, there was no correlation determined between tissue and serum levels of all biomarkers and mutation percentages of Ki67 and p53 (p > 0.05). CONCLUSION: EC and VEGF121 are biomarkers, which have the potential to be used in the diagnosis, recurrence and treatment follow-up in high graded glial tumors (Tab. 2, Fig. 1, Ref. 37). Text in PDF www.elis.sk
dc.identifier.doi10.4149/BLL_2023_046
dc.identifier.endpage308
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue4en_US
dc.identifier.pmid36598325
dc.identifier.scopus2-s2.0-85150000414
dc.identifier.scopusqualityQ3
dc.identifier.startpage304
dc.identifier.urihttps://doi.org/10.4149/BLL_2023_046
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12105
dc.identifier.volume124
dc.identifier.wosWOS:000957700000009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÖznur, Meltem
dc.language.isoen
dc.publisherAepress Sro
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectfollow-up high graded glial (Tab
dc.subject2
dc.subjectFig
dc.subject1
dc.subject37)
dc.subjectKEY WORDS
dc.subjectE-Cadherin
dc.subjectVEGF
dc.subjectSurvivin
dc.subjectTenascin-C
dc.subjectTetraspanin
dc.subjectglioblastoma
dc.subjectEndothelial Growth-Factor
dc.subjectCentral-Nervous-System
dc.subjectExpression
dc.subjectTumors
dc.subjectBrain
dc.subjectOrganization
dc.subjectRelevance
dc.subjectApoptosis
dc.subjectBiology
dc.titleInvestigation of serum E-Cadherin, VEGF121, Survivin, Tenascin C and Tetraspanin 8 levels in patients with glioblastoma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12105.pdf
Boyut:
223.86 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu